SC-99

CAS No. 882290-02-0

SC-99( STAT3 inhibitor SC99 )

Catalog No. M16398 CAS No. 882290-02-0

A novel selective STAT3 inhibitor that inhibits JAK2-STAT3 activation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 170 Get Quote
10MG 263 Get Quote
25MG 504 Get Quote
50MG 709 Get Quote
100MG 1008 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SC-99
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel selective STAT3 inhibitor that inhibits JAK2-STAT3 activation.
  • Description
    A novel selective STAT3 inhibitor that inhibits JAK2-STAT3 activation but has no effects on other transcription factors such as NF-κB, and kinases such as AKT, ERK, and c-Src; inhibits STAT3 phosphorylation, dimerization and nuclear translocation, downregulates STAT3-modulated gene expression and induces MM cell apoptosis; delays tumor growth in MM xenograft models (30mg/kg); orally active.
  • In Vitro
    SC99 (10 or 30 μM; for 72 hours) induces MM cell death. SC99 (10 μM; 24 hours) decreases the p-STAT3 level but has no effects on total STAT3 expression. SC99 (2.5, 5, 10, 20 μM; for 60 mins) inhibits JAK2 phosphorylation in a concentration-dependent manner but does not inhibit the phosphorylation levels of AKT, ERK, mTOR or c-Src at a concentration up to 20 μM. SC99 (1.25, 2.5, 5 μM; pre-treated for 10 min) inhibits collagen (2 μg/mL) and thrombin (0.02 U/mL) induced phosphorylation of STAT3 in a concentration-dependent manner. SC99 (pre-treated for 2 hours) inhibits IL-6 (50 ng/ml; for 20 min) induced STAT3 nucleartranslocation in OPM2 cells.Apoptosis Analysis Cell Line:Six multiple myeloma (MM) cell lines (LP1, JJN3, RPMI-8226, U266, OPM2 and OCI-MY5)Concentration:10 or 30 μM Incubation Time:For 72 hours Result:Induced MM cell death.Apoptosis Analysis Cell Line:MM cell lines Concentration:10 μM Incubation Time:24 hours Result:Decreased the p-STAT3 level but had no effects on total STAT3 expression in all cell lines examined.
  • In Vivo
    SC99 (30 mg/kg; orally; daily; for continuous 14 or 28 days) delays myeloma tumor growth in xenograft mice models. SC99 (5, 10,?15 mM, 15?μL; ICV) produces an effective inhibitory effect on the phosphorylation of JAK2 and STAT3 in middle cerebral artery occlusion and reperfusion (MCAO/R) model (adult male SD rats; 250-300?g). SC99 ameliorates neuronal apoptosis and degeneration, neurobehavioral deficits, inflammatory response and brain edema. Animal Model:Nude mice with Human MM cells OPM2 or JJN3 Dosage:30 mg/kg Administration:Orally; daily; for continuous 14 or 28 daysResult:Delayed myeloma tumor growth in xenograft mice models and suppressed tumor growth more than 40% in 14 days in the OPM2 model.
  • Synonyms
    STAT3 inhibitor SC99
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    STAT
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    882290-02-0
  • Formula Weight
    336.147
  • Molecular Formula
    C15H8Cl2FN3O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (247.90 mM)
  • SMILES
    N#C/C(C(C1=CC=C(Cl)C=C1)=O)=N\NC2=CC=C(F)C(Cl)=C2
  • Chemical Name
    (E)-N-(3-chloro-4-fluorophenyl)-2-(4-chlorophenyl)-2-oxoacetohydrazonoyl cyanide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhang Z, et al. Oncotarget. 2016 Feb 23;7(8):9296-308. 2. Xu Z, et al. Acta Pharmacol Sin. 2017 May;38(5):651-659.
molnova catalog
related products
  • BTA-9881

    BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

  • GPA 512

    The orally bioavailable prodrug of Galiellalactone, a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes.

  • S3I-M2001

    S3I-M2001 (Bromohydroxyacetone phosphate) is an oxazole-based peptidomimetic of the STAT3 SH2 domain-binding phosphotyrosine peptide that selectively disrupts active STAT3:STAT3 dimers.